Brokerages forecast that RXi Pharmaceuticals Corp (NASDAQ:RXII) will post earnings of ($0.56) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for RXi Pharmaceuticals’ earnings. RXi Pharmaceuticals reported earnings of ($1.10) per share during the same quarter last year, which suggests a positive year over year growth rate of 49.1%. The business is expected to report its next quarterly earnings report on Thursday, August 9th.
According to Zacks, analysts expect that RXi Pharmaceuticals will report full year earnings of ($2.50) per share for the current fiscal year. For the next fiscal year, analysts forecast that the firm will post earnings of ($1.75) per share. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow RXi Pharmaceuticals.
RXi Pharmaceuticals (NASDAQ:RXII) last posted its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.90) earnings per share for the quarter. The company had revenue of $0.02 million for the quarter.
Separately, ValuEngine raised shares of RXi Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, April 2nd.
Shares of RXi Pharmaceuticals opened at $2.33 on Thursday, according to Marketbeat Ratings. RXi Pharmaceuticals has a twelve month low of $1.90 and a twelve month high of $7.70. The stock has a market capitalization of $10.55 million, a price-to-earnings ratio of -0.55 and a beta of 1.15.
RXi Pharmaceuticals Company Profile
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.